BiotechTube
Vax-Immune

Vax-Immune

San Diego, United States· Est.
labready.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Vax-Immune (LabReady) is pioneering a disruptive point-of-need diagnostic platform that combines rugged, portable hardware, multiplex qPCR assays, and onboard AI verification. Its flagship product, MyLabReady, aims to detect up to five pathogens in approximately 15 minutes without requiring a lab, refrigeration, or specialized technical expertise, targeting markets from clinics to farms. The company is currently in the development and regulatory approval stage, positioning itself to address critical gaps in rapid, accurate diagnostic testing across multiple sectors. Its business model appears focused on diagnostics, with a 'no upfront costs' strategy suggesting a reagent/consumable or subscription-based revenue model.

Infectious Disease

Technology Platform

Portable, AI-enabled multiplex qPCR diagnostic system (MyLabReady) designed for simple, point-of-need use without lab infrastructure, refrigeration, or specialized training.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The growing demand for rapid, decentralized diagnostics in human healthcare (clinics, ERs, pharmacies) and agriculture (farm-level pathogen detection) presents a large, dual-market opportunity.
The platform's ability to deliver lab-grade, multiplex results in minutes could displace slower central lab testing and less accurate rapid tests, particularly if reimbursement for multiplex panels is secured.

Risk Factors

The company faces significant regulatory risk as its products are pending approval, and failure to clear FDA or other agencies would be catastrophic.
It also faces intense competition from established diagnostics firms and must successfully execute on complex manufacturing, commercialization, and fundraising in a capital-intensive sector.

Competitive Landscape

LabReady competes in the point-of-care molecular diagnostics space against large, established players like Cepheid (GeneXpert) and Abbott (ID Now), which offer portable systems but with varying degrees of multiplexing and speed. It also faces competition from numerous startups developing portable PCR and is up against entrenched rapid antigen tests and traditional central laboratory services.

More companies in Diagnostics & Precision Medicine →More companies in United States →